Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

121. Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma

Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma 28653142 2017 06 27 2017 06 27 1432-2323 2017 Jun 26 World journal of surgery World J Surg Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. 10.1007/s00268-017-4097-1 The Controlling Nutritional Status (CONUT) score is an objective tool (...) widely used to assess nutritional status in patients with inflammatory disease, chronic heart failure, and chronic liver disease. The relationship between CONUT score and prognosis in patients who have undergone hepatic resection, however, has not been evaluated. Data were retrospectively collected for 357 consecutive patients with hepatocellular carcinoma (HCC) who had undergone hepatic resection with curative intent between January 2004 and December 2015. The patients were assigned to two groups

EvidenceUpdates2017

122. [Tenofovir alafenamide (chronic hepatitis B) - benefit assessment according to õ35a Social Code Book V ]

[Tenofovir alafenamide (chronic hepatitis B) - benefit assessment according to õ35a Social Code Book V ] Tenofoviralafenamid (chronische hepatitis B): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-1 [Tenofovir alafenamide (chronic hepatitis B) – benefit assessment according to §35a Social Code Book V ] Tenofoviralafenamid (chronische hepatitis B): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-1 [Tenofovir alafenamide (chronic hepatitis B) – benefit (...) assessment according to §35a Social Code Book V ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tenofoviralafenamid (chronische hepatitis B): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-1

Health Technology Assessment (HTA) Database.2017

123. Glecaprevir and pibrentasvir (Mavyret) - To treat adults with chronic hepatitis C virus

Glecaprevir and pibrentasvir (Mavyret) - To treat adults with chronic hepatitis C virus Drug Approval Package: MAVYRET (glecaprevir and pibrentasvir) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: MAVYRET (glecaprevir and pibrentasvir) Company: AbbVie Inc. Application No.: 209394Orig1s000 Approval Date: August 3, 2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF

FDA - Drug Approval Package2017

124. Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) - To treat adults with chronic hepatitis C virus

Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) - To treat adults with chronic hepatitis C virus Drug Approval Package: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) Company: Gilead Sciences, Inc. Application No.: 209195Orig1s000 Approval Date: July 18, 2017 Persons with disabilities having problems accessing the PDF files below may call (301

FDA - Drug Approval Package2017

125. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Background: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high rates of disease cure; however, not enough specialists currently are available to provide care. Objective: To determine the efficacy of HCV treatment independently provided by nurse practitioners (NPs), primary care physicians (PCPs

Annals of Internal Medicine2017

126. Ibrutinib (Imbruvica): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections

Ibrutinib (Imbruvica): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections - GOV.UK GOV.UK uses cookies to make the site simpler. Search Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections From: Published: 15 August 2017 Therapeutic area (...) : , , , , and Temporarily discontinue ibrutinib in patients who develop symptoms suggestive of ventricular arrhythmia and assess benefit-risk before restarting therapy. Establish hepatitis B virus status before initiating ibrutinib. Consider prophylaxis for patients who are at an increased risk of opportunistic infections. Contents Advice for healthcare professionals: cases of ventricular tachyarrhythmia have been reported temporarily discontinue ibrutinib in patients who develop symptoms suggestive of ventricular

MHRA Drug Safety Update2017

127. Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation

Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation - GOV.UK GOV.UK uses cookies to make the site simpler. Search Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor (...) for opportunistic infections, hepatitis B reactivation From: Published: 20 July 2017 Therapeutic area: , , and Recent clinical trials have shown increased mortality when bendamustine (Levact) was used in combination treatments outside its approved indications. Be aware that the risk of opportunistic infections for all patients receiving bendamustine including those receiving off-label treatment may be greater than previously recognised. Be aware of your responsibilities if prescribing bendamustine outside

MHRA Drug Safety Update2017

132. Message from Dr Mahmoud Fikri Regional Director, WHO Eastern Mediterranean Region, on the occasion of World Hepatitis Day, 28 July 2017

Message from Dr Mahmoud Fikri Regional Director, WHO Eastern Mediterranean Region, on the occasion of World Hepatitis Day, 28 July 2017 WHO IRIS: Message from Dr Mahmoud Fikri Regional Director, WHO Eastern Mediterranean Region, on the occasion of World Hepatitis Day, 28 July 2017 Browse Related links Files in This Item: File Description Size Format 24.5 kB Adobe PDF Title: Message from Dr Mahmoud Fikri Regional Director, WHO Eastern Mediterranean Region, on the occasion of World Hepatitis Day

WHO2017

133. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.

Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. BACKGROUND: Hepatic encephalopathy is a common complication of cirrhosis which results in poor brain functioning. The spectrum of changes associated with hepatic encephalopathy ranges from the clinically 'indiscernible' or minimal hepatic encephalopathy to the clinically 'obvious' or overt hepatic encephalopathy. Flumazenil is a synthetic benzodiazepine antagonist with high affinity (...) for the central benzodiazepine recognition site. Flumazenil may benefit people with hepatic encephalopathy through an indirect negative allosteric modulatory effect on gamma-aminobutyric acid receptor function. The previous version of this review, which included 13 randomised clinical trials, found no effect of flumazenil on all-cause mortality, based on an analysis of 10 randomised clinical trials, but found a beneficial effect on hepatic encephalopathy, based on an analysis of eight

Cochrane2017

134. Hepatitis B vaccines: WHO position paper – July 2017 – Vaccins anti-hépatite B: note de synthèse de l’OMS – juillet 2017

Hepatitis B vaccines: WHO position paper – July 2017 – Vaccins anti-hépatite B: note de synthèse de l’OMS – juillet 2017 WHO IRIS: Hepatitis B vaccines: WHO position paper – July 2017 – Vaccins anti-hépatite B: note de synthèse de l’OMS – juillet 2017 Browse Related links Files in This Item: File Description Size Format 441.01 kB Adobe PDF Title: Hepatitis B vaccines: WHO position paper – July 2017 – Vaccins anti-hépatite B: note de synthèse de l’OMS – juillet 2017 Authors: Issue Date: 7-Jul

WHO2017

135. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON)

Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON) 28329061 2017 03 22 2017 06 12 2017 06 13 1537-6613 215 7 2017 04 01 The Journal of infectious diseases J. Infect. Dis. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized (...) , Controlled Trial (PEGON). 1085-1093 10.1093/infdis/jix024 We studied whether 48 weeks of pegylated interferon alfa-2b (peginterferon) add-on therapy increases serological response in hepatitis B virus (HBV) envelope antigen (HBeAg)-positive patients receiving nucleos(t)ide analogue (NA) therapy, compared with continued NA monotherapy. This randomized trial included HBeAg-positive patients with compensated liver disease who were treated with entecavir/tenofovir for >12 months and had an HBV DNA load

EvidenceUpdates2017

136. Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014.

Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014. Background: In the United States, hepatitis C virus (HCV) infection has increased among young persons who inject drugs, but the extent of this epidemic among reproductive-aged women and their children is unknown. Objective: To estimate numbers and describe characteristics of reproductive-aged women with HCV infection and of their offspring. Design: Analysis of the National Notifiable

Annals of Internal Medicine2017

137. Spotlight: Hepatic Encephalopathy and TIPS: A Clinical Vignette

Spotlight: Hepatic Encephalopathy and TIPS: A Clinical Vignette Spotlight: Hepatic Encephalopathy and TIPS: A Clinical Vignette | Clinical Correlations Spotlight: Hepatic Encephalopathy and TIPS: A Clinical Vignette April 26, 2017 By Samantha Kass Newman, MD Peer Reviewed Today marks the first publication of the new Spotlight series in Clinical Correlations. This series uses case vignettes to explore diagnosis, pathophysiology, and management of a wide variety of diseases seen in the outpatient (...) and inpatient settings. Articles in the Spotlight section contain clinical pearls that will be highlighted in the case discussion. While the occasional zebra may appear, the goal of the series is to provide clinically relevant information, and each case has been selected specifically for the relevance of its learning points rather than its rarity. LEARNING OBJECTIVES What is the cause of hepatic encephalopathy? Why does placement of a transjugular intrahepatic portosystemic shunt (TIPS) increase the risk

Clinical Correlations2017

138. In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA

In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA 28043903 2017 01 03 2017 04 03 1528-0012 152 5 2017 Apr Gastroenterology Gastroenterology In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. 1068-1077.e4 S0016 (...) -5085(16)35533-0 10.1053/j.gastro.2016.12.019 Infections are common in patients with severe alcoholic hepatitis (SAH), but little information is available on how to predict their development or their effects on patients. Prednisolone is advocated for treatment of SAH, but can increase susceptibility to infection. We compared the effects of infection on clinical outcomes of patients treated with and without prednisolone, and identified risk factors for development of infection in SAH. We analyzed

EvidenceUpdates2017

139. Recommendations on hepatitis C screening for adults

Recommendations on hepatitis C screening for adults ');//--> Search in: COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2016 American Society of Clinical Oncology | |

CMA Infobase (Canada)2017

140. Elbasvir/grazoprevir (chronic hepatitis C): Benefit assessment according to õ35a Social Code Book V

Elbasvir/grazoprevir (chronic hepatitis C): Benefit assessment according to õ35a Social Code Book V Elbasvir/Grazoprevir (chronische Hepatitis C): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-75 [Elbasvir/grazoprevir (chronic hepatitis C): Benefit assessment according to §35a Social Code Book V] Elbasvir/Grazoprevir (chronische Hepatitis C): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-75 [Elbasvir/grazoprevir (chronic hepatitis C): Benefit assessment (...) according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Elbasvir/Grazoprevir (chronische Hepatitis C): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-75. [Elbasvir

Health Technology Assessment (HTA) Database.2017